Galena Biopharma begins phase 1/2 study of FBP vaccine
The FBP vaccine comprises E39 peptide integrated with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF). The study will examine if the FBP vaccine is safe and effective
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.